Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period.
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Colon cancer
- Focus Pharmacodynamics; Proof of concept
- Acronyms ImPACCT
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2016 Status changed from not yet recruiting to recruiting.
- 26 Nov 2015 New trial record